Compare Ascendis Pharma A/S (ASND) vs Bill.com Holdings Inc (BILL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Bill.com Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Bill.com Holdings Inc trades at $41.2 (market cap $4.12B). The key difference: Ascendis Pharma A/S is far larger — about 4.3× Bill.com Holdings Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | BILL | |
|---|---|---|
Market Cap | $17.74B | $4.12B |
Sector | Health | Technology |
52-Week High | $277.18 | $56.32 |
52-Week Low | $163.32 | $31.96 |
Enterprise Value | $18.11B | $3.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BILL Holdings trades at $41.36, up 2.07% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical outlook with support at $39 and resistance at $42. Revenue growth accelerated to $1.46 billion in 2025, though net margins remain thin at 0.01%. Recent leadership changes and a $1 billion buyback program signal confidence in future growth.
Outlook remains positive with 56% analyst buy ratings and a $48 consensus target suggesting 16% upside. Key risks include high valuation (P/E 214), competitive pressures in SMB software, and sensitivity to interest rate changes. The company's transition to profitability and AI integration present opportunities if execution continues improving.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →
